Back

PCSK9 inhibition: from biology to clinical applications.

31 August 2020 (09:26 - 09:37)
Organised by:
Congress Presentation Part of: Atherothrombosis: New Therapeutic Targets Pharmacology and Pharmacotherapy, Other ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Gilles Lambert

INSERM, SAINT DENIS (Réunion)

3 More presentations in this session

Presentation thumbnail
RNA-targeting therapeutics for lipid disorders.
Professor S. Tsimikas (La Jolla, US)
Video
Presentation thumbnail
Targeting new coagulation factors in atherothrombosis.
Professor H. Ten Cate (Maastricht, NL)
Slides Video
Presentation thumbnail
The inflammasome: old drugs and new insights.
Doctor J. Tardif (Montreal, CA)
Slides Video

Access the full session

Session thumbnail
Atherothrombosis: New Therapeutic Targets

The Event

Event poster

ESC Congress 2020

31 August 2020 09:26 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
26 August 2022
thumbnail
Webinar
Lipid management pathways and ESC Guidelines
10 January 2023
thumbnail
Congress Presentation
Identification of potent small-molecule PCSK9 inhibitors based on quantitative structure-activity relationship, pharmacophore modeling, and molecular docking procedure.
28 August 2023
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources